PMEL and neoplasm: While M-gp100.2L provided no enhancement of survival compared to the nonmannosylated gp100.2L VLP, dimannosylation significantly enhanced mouse survival compared to the nonmannosylated gp100.2L, with one mouse remaining tumour-free to day 70 (Figure 4(d)).